LeMaitre Vascular (NASDAQ:LMAT) Lowered to Market Perform Rating by Barrington Research

LeMaitre Vascular (NASDAQ:LMAT) was downgraded by equities researchers at Barrington Research from an “outperform” rating to a “market perform” rating in a research note issued to investors on Wednesday, Marketbeat.com reports.

A number of other equities research analysts have also recently commented on the company. Wall Street Zen cut LeMaitre Vascular from a “buy” rating to a “hold” rating in a research report on Saturday. Citigroup reissued a “market outperform” rating on shares of LeMaitre Vascular in a report on Tuesday, July 21st. Weiss Ratings lowered shares of LeMaitre Vascular from a “buy (b)” rating to a “buy (b-)” rating in a research report on Tuesday, June 30th. Wells Fargo & Company lifted their price objective on LeMaitre Vascular from $94.00 to $104.00 and gave the stock an “equal weight” rating in a report on Wednesday, May 6th. Finally, Zacks Research downgraded LeMaitre Vascular from a “strong-buy” rating to a “hold” rating in a research note on Monday, July 6th. Four research analysts have rated the stock with a Buy rating and five have given a Hold rating to the stock. According to data from MarketBeat.com, the stock has an average rating of “Hold” and an average price target of $112.60.

LeMaitre Vascular Price Performance

Shares of NASDAQ:LMAT opened at $105.78 on Wednesday. The company has a market cap of $2.42 billion, a PE ratio of 39.03, a price-to-earnings-growth ratio of 2.88 and a beta of 0.53. The company’s 50 day moving average is $97.41 and its 200 day moving average is $100.04. LeMaitre Vascular has a twelve month low of $79.39 and a twelve month high of $118.01. The company has a current ratio of 14.32, a quick ratio of 12.20 and a debt-to-equity ratio of 0.42.

LeMaitre Vascular (NASDAQ:LMAT) last issued its earnings results on Tuesday, August 4th. The medical instruments supplier reported $0.74 EPS for the quarter, missing analysts’ consensus estimates of $0.81 by ($0.07). LeMaitre Vascular had a return on equity of 15.36% and a net margin of 24.35%.The company had revenue of $70.38 million during the quarter, compared to analysts’ expectations of $71.47 million. During the same quarter in the previous year, the company earned $0.60 EPS. The firm’s quarterly revenue was up 9.6% compared to the same quarter last year. On average, sell-side analysts forecast that LeMaitre Vascular will post 3 EPS for the current year.

Insider Activity at LeMaitre Vascular

In related news, CEO George W. Lemaitre sold 27,881 shares of the firm’s stock in a transaction dated Friday, May 8th. The shares were sold at an average price of $108.69, for a total transaction of $3,030,385.89. Following the completion of the sale, the chief executive officer directly owned 1,430,019 shares in the company, valued at approximately $155,428,765.11. This trade represents a 1.91% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, insider Trent G. Kamke sold 2,928 shares of LeMaitre Vascular stock in a transaction that occurred on Friday, May 8th. The shares were sold at an average price of $107.00, for a total transaction of $313,296.00. Following the sale, the insider directly owned 3,749 shares in the company, valued at approximately $401,143. The trade was a 43.85% decrease in their position. The SEC filing for this sale provides additional information. Over the last quarter, insiders sold 54,453 shares of company stock valued at $5,906,174. 7.40% of the stock is owned by company insiders.

Hedge Funds Weigh In On LeMaitre Vascular

Institutional investors have recently bought and sold shares of the company. Sound Income Strategies LLC raised its stake in shares of LeMaitre Vascular by 425.6% in the first quarter. Sound Income Strategies LLC now owns 226 shares of the medical instruments supplier’s stock valued at $25,000 after acquiring an additional 183 shares in the last quarter. Catalyst Capital Advisors LLC acquired a new position in shares of LeMaitre Vascular during the first quarter worth $32,000. Geneos Wealth Management Inc. increased its holdings in LeMaitre Vascular by 250.3% in the first quarter. Geneos Wealth Management Inc. now owns 557 shares of the medical instruments supplier’s stock valued at $47,000 after buying an additional 398 shares during the last quarter. EverSource Wealth Advisors LLC purchased a new stake in LeMaitre Vascular during the 2nd quarter worth about $47,000. Finally, Quarry LP lifted its holdings in LeMaitre Vascular by 267.2% during the 3rd quarter. Quarry LP now owns 727 shares of the medical instruments supplier’s stock worth $64,000 after buying an additional 529 shares during the last quarter. 84.64% of the stock is owned by institutional investors and hedge funds.

Key Stories Impacting LeMaitre Vascular

Here are the key news stories impacting LeMaitre Vascular this week:

• Positive Sentiment: Second-quarter revenue increased 9.6% year over year to $70.38 million, while EPS rose to $0.74 from $0.60 a year earlier. The company also maintained strong profitability, with a 24.35% net margin. LeMaitre Q2 2026 Financial Results
• Positive Sentiment: LeMaitre declared a quarterly dividend of $0.25 per share, payable September 3 to shareholders of record on August 20. The dividend equates to an annualized yield of approximately 0.9%, providing a modest shareholder-return benefit.
• Neutral Sentiment: Management discussed the quarter and outlook on its Q2 2026 earnings call, giving investors additional context on operating trends and expectations. LeMaitre Vascular Q2 2026 Earnings Call Transcript
• Negative Sentiment: Q2 EPS of $0.74 missed the $0.81 consensus estimate, and revenue of $70.38 million was below the $71.47 million forecast. The earnings shortfall is particularly important because LMAT trades at a relatively elevated valuation.
• Negative Sentiment: LeMaitre reduced its full-year 2026 outlook to EPS of $2.84-$2.94 and revenue of $274.3-$278.3 million, below consensus estimates of $3.00 and $279.9 million, respectively. Third-quarter guidance was also below expectations, with EPS of $0.66-$0.71 versus $0.73 consensus and revenue of $66.3-$68.3 million versus $69.0 million. LeMaitre Vascular Q2 Earnings and Revenues Lag Estimates

About LeMaitre Vascular

LeMaitre Vascular, Inc is a specialty medical device company focused on the development, manufacture and marketing of products for the treatment of peripheral vascular disease. Headquartered in Burlington, Massachusetts, the company’s offerings include a broad portfolio of vascular surgical instruments, grafts, patches, catheters and embolic protection devices. LeMaitre’s product lines address key areas such as arterial reconstruction, endovascular repair and vascular access, serving the needs of cardiovascular surgeons and interventional specialists.

Founded in 1983 by George D.